TAYSHA GENE THERAPIES INC
NASDAQ: TSHA (Taysha Gene Therapies, Inc.)
最近更新时间: 22小时之前4.10
-0.11 (-2.61%)
AIStockmoo 评分
| 价值 30% | -1.4 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 资本回报 参考 | NA |
| 时机 30% | -2.4 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年没有明确趋势。股价远低于52周高点。 参考 | |
| K线形态 参考 | NA |
| 您持有期的趋势 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | 3.2 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净+10.38%的股份:137家增持,74家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+14.3%,回补天数14.8天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短期动能上升。 参考 | |
| 股价接近支撑位。支撑与阻力水平趋降。 参考 | |
| 最终评分 | -0.49 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Taysha Gene Therapies, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| TSHA | - | - | - | 3.74 |
| VRNA | 9 B | - | - | 33.01 |
| OPT | 583 M | - | - | 4.31 |
| VRCA | - | - | - | 15.60 |
| ABEO | - | - | - | 1.04 |
| VKTX | - | - | - | 6.33 |
|
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 12.11% |
| 机构持股比例 | 67.23% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Polar Capital Holdings Plc | 30 Jun 2026 | 5,117,133 |
该时间范围内无数据。
机构
机构持股比例: 97.20%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 137 | 37,295,049 |
| 减持 | 74 | 15,115,926 |
| 新建仓 | 43 | 16,801,077 |
| 清仓 | 22 | 5,137,834 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 53,478,497 | 14.8 |
| 15 Oct 2026 | 51,249,292 | 11.6 |
| 30 Sep 2026 | 55,020,663 | 11.2 |
| 15 Sep 2026 | 51,405,384 | 18.8 |
| 31 Aug 2026 | 46,800,424 | 19.4 |
| 14 Aug 2026 | 46,738,149 | 17.4 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
Taysha (TSHA) Q3 2026 Earnings Call Transcript
Management says 33 patients dosed so far with no severe treatment-related events. |
| 12 Nov 2026 | Yahoo Finance |
Taysha Gene Therapies Q3 Earnings Call Highlights
Taysha Gene Therapies (NASDAQ:TSHA) expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing pathway in the first half of 2027, executives said on the company’s third-quarter earnings call. The comp… |
| 12 Nov 2026 | Yahoo Finance |
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across… |
| 06 Nov 2026 | Yahoo Finance |
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today… |
| 05 Nov 2026 | Yahoo Finance |
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
DALLAS, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today… |
| 30 Oct 2026 | Yahoo Finance |
Taysha Gene Therapies (TSHA) Stock Looks Rich Against Book Value
Taysha Gene Therapies has seen sharp swings in its share price over recent years, and that volatility puts a spotlight on a basic question for holders: Is the market value you see on screen today in line with what its balance sheet and book value can reasonably support? Over the past 3 years the… |
| 18 Oct 2026 | Yahoo Finance |
Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
Taysha Gene Therapies reported phase 1/2 REVEAL data in Rett syndrome, where all 10 participants receiving a single intrathecal TSHA-102 dose gained or regained at least one developmental milestone and no treatment-related serious adverse events were observed. These findings support the therapy's… |
| 09 Oct 2026 | Yahoo Finance |
Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
Taysha Gene Therapies has delivered a 90.1% gain over the past three years, which puts fresh attention on whether that kind of move is backed up by the value on its balance sheet. With the share price at US$4.43 at the last close, the live question is how comfortably that level sits against the… |
| 09 Oct 2026 | Yahoo Finance |
Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
Taysha Gene Therapies (TSHA) has drawn fresh attention after a period of pressure on the share price, with the stock roughly flat over the past day but lower over the past month and the past three months. Short term momentum for Taysha Gene Therapies has clearly cooled, with the 7 day share price… |
| 01 Oct 2026 | Yahoo Finance |
Taysha Gene Therapies Announces Multiple Encore Presentations Supporting TSHA-102 Rett Syndrome Clinical Program at the 55th Child Neurology Society Annual Meeting
DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today… |
| 07 Sep 2026 | Yahoo Finance |
These 3 Risky Stocks Could Be Sitting on 100% Upside
Analysts see high-risk, high-reward potential in Red Cat Holdings, Taysha Gene Therapies, and Solaris Resources, each projected to roughly double despite significant company-specific risks. |
| 18 Aug 2026 | Yahoo Finance |
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
TSHA-102 dosing complete in pivotal Rett syndrome trials with 100% responder rate. |
| 显示更多 | ||
投资组合